Details of the Drug

General Information of Drug (ID: DMKBW5C)

Drug Name

Talimogene Laherparepvec

Synonyms

IMLYGIC

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Vaccine

ADMET Property

Bioavailability: The bioavailability of drug is 100% [2]
Elimination: In an ongoing melanoma study, interim results from 30 patients show that talimogene laherparepvec DNA was detected at transient and low concentrations in blood in 90% of patients and in urine in 20% of patients in the study, which suggests that perhaps at least some portion of the drug is eliminated in the urine [3]
Metabolism: The drug is metabolized via the common endogenous protein and DNA catabolic pathways [4]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Granulocyte-macrophage colony-stimulating factor (CSF2)	TTNYZG2	CSF2_HUMAN	Modulator	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Melanoma

ICD Disease Classification

2C30

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Granulocyte-macrophage colony-stimulating factor (CSF2)	DTT	CSF2	2.36E-01	-0.06	-0.26

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Metoprolol .
3	EMA: Imylgic (talimogene laherparepvec) prescribing information
4	Electronic Medicines Compendium: Imlygic (talimogene laherparepvec) monograph
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.